KARD (Kardigan) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KARD Kardigan Inc KARD
12 GF Score
Price $16.64
! 1 Warning Sign
View Full Analysis

What is Kardigan Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kardigan's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $3.75 Mil. Kardigan's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $9.60 Mil. Kardigan's annualized EBITDA for the quarter that ended in Jun. 2026 was $-456.18 Mil. Kardigan's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was -0.03.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Kardigan's Debt-to-EBITDA or its related term are showing as below:

KARD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.1   Med: -0.09   Max: -0.07
Current: -0.1

During the past 2 years, the highest Debt-to-EBITDA Ratio of Kardigan was -0.07. The lowest was -0.10. And the median was -0.09.

KARD's Debt-to-EBITDA is ranked worse than
100% of 304 companies
in the Biotechnology industry
Industry Median: 1.215 vs KARD: -0.10

Kardigan  (NAS:KARD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Kardigan Debt-to-EBITDA Related Terms

Kardigan Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Kardigan's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kardigan Debt-to-EBITDA Chart

Kardigan Annual Data
Trend Dec24 Dec25
Debt-to-EBITDA
- -

Kardigan Quarterly Data
Mar25 Jun25 Mar26 Jun26
Debt-to-EBITDA - - - -

KARD vs TSHA, VIR, GHRS: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Kardigan's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kardigan Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kardigan's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kardigan's Debt-to-EBITDA falls into.


KARD
12GF Score
Kardigan Inc KARD
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kardigan Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kardigan's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.143 + 10.689) / -190.71
=-0.07

Kardigan's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.752 + 9.595) / -456.184
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Kardigan Business Description

Address 506 Carnegie Center Drive, Suite 201, Princeton, NJ, USA, 08540
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
12GF Score

Get the complete analysis for KARD

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.64
Price